Answers are grounded in this paper and cite their sources.
Review highlights improved drug delivery and bioavailability in atopic dermatitis treatment using lipid nanocarriers, indicating promising therapeutic efficiency.
Atopic dermatitis (AD), otherwise known as atopic eczema, is a prominent and worsening chronic inflammatory condition of the skin, marked by eczematous lacerations and intense burning in multiple body parts. Approximately 20% of both children and adults worldwide are affected by atopic dermatitis (AD). Topical remedial treatment is the foundation of AD management. Traditional treatments consist of the use of topical corticosteroids as the preferred therapy, though in some cases of AD, antihistamines, calcineurin inhibitors, antibiotics, phototherapy, and immunosuppressant drugs are also considered. Due to the skin’s anatomic barrier, topical delivery of drugs to deeper layers is a complicated task, which restricts deeper penetration. Because of their inability to penetrate the epidermis, clinical medications are associated with harmful consequences that outweigh efficacy and safety constraints, resulting in reduced patient compliance. The use of nanotechnology has emerged as a promising technique for treating AD, allowing for regulated release, greater penetration, targeted distribution, and improved bioavailability of pharmacological agents, which results in significantly enhanced therapeutic efficiency and reduced unwanted effects. In conclusion, the integration of topical lipid nanocarriers in AD treatment showcases substantial potential, offering advantages in targeted drug delivery, stability, and skin barrier enhancement.
No takes yet. Share an insight, caveat, or question.
Bhadauria et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: